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Abstract
 
The complement system is an essential component of host defense against pathogens. Previous
research in our laboratory identified StcE, a metalloprotease secreted by 
 
Escherichia coli
 
 O157:
H7 that cleaves the serpin C1 esterase inhibitor (C1-INH), a major regulator of the classical
complement cascade. Analyses of StcE-treated C1-INH activity revealed that surprisingly, StcE
enhanced the ability of C1-INH to inhibit the classical complement-mediated lysis of sheep
erythrocytes. StcE directly interacts with both cells and C1-INH, thereby binding C1-INH to
the cell surface. This suggests that the augmented activity of StcE-treated C1-INH is due to the
increased concentration of C1-INH at the sites of potential lytic complex formation. Indeed,
removal of StcE abolishes the ability of C1-INH to bind erythrocyte surfaces, whereas the proteoly-
sis of C1-INH is unnecessary to potentiate its inhibitory activity. Physical analyses showed that
StcE interacts with C1-INH within its aminoterminal domain, allowing the unaffected serpin
domain to interact with its targets. In addition, StcE-treated C1-INH provides significantly
increased serum resistance to 
 
E. coli
 
 K-12 over native C1-INH. These data suggest that by
recruiting C1-INH to cell surfaces, StcE may protect both 
 
E. coli
 
 O157:H7 and the host cells
to which the bacterium adheres from complement-mediated lysis and potentially damaging
inflammatory events.
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Introduction
 
Innate mechanisms of immunity are fundamental compo-
nents of host defense and are essential for the detection
and clearance of many invading pathogens. Among them,
the complement system serves multiple functions, includ-
ing opsonization and lysis of organisms, production of
chemoattractant molecules, mediation of inflammation,
and augmentation of humoral immunity (for review see
reference 1). Acting in a series of interlinked proteolytic
cascades comprised of multiple serine proteases, complement
pathways are rapidly up-regulated and the components are
amplified upon activation. To protect the host from the
adverse inflammatory and cytolytic effects resulting from
complement activation, multiple factors exist to prevent
unregulated complement activity (2–5).
One of these factors is C1 esterase inhibitor (C1-INH),
an essential regulator of classical complement, intrinsic co-
agulation, and contact activation (for review see reference 6).
C1-INH is a member of the serine protease inhibitor (ser-
pin) family of molecules, which includes antithrombin,
 
 
 
-1-antitrypsin, and plasminogen activator type-1 (7). Ser-
pins control multiple proteolytic cascades in the body by non-
enzymatically inactivating target serine proteases in a 1:1
stoichiometric ratio. Serpins interact with their targets via
the serpin reactive center loop (RCL) which, when cleaved
by the serine protease, inserts into the target molecule. This
insertion irreversibly displaces the active serine of the protease
from its catalytic partners (8).
C1-INH is the only known inhibitor of activated C1r
and C1s of the classical complement cascade and the MASP
1 and 2 proteases of the mannose-binding ligand pathway,
and is a major inhibitor of Factor XIIa (Hageman Factor),
kallikrein, and Factor XIa of the inflammation, fibrinolysis,
and the intrinsic coagulation pathways (9–14). Additionally,
C1-INH competes with Factor B for binding to C3b to
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inhibit the activation of the alternative complement path-
way (15). C1-INH is a heavily glycosylated protein and the
majority of the posttranslational modifications occur within
the aminoterminal domain unique to this serpin. Interest-
ingly, removal of this domain does not affect the ability of
C1-INH to interact with or inhibit its targets (16, 17). As
with other serpins, glycosaminoglycans can potentiate the
inhibitory capacity of C1-INH, although the effect of po-
tentiation differs depending on the substrate (18, 19). C1-
INH forms large SDS-insoluble complexes with its target
proteases that are subsequently removed from circulation
(6). In addition to its soluble form, cell-associated C1-INH
may protect cells from proinflammatory events at their sur-
face (6, 20, 21). However, the mechanism by which this
form of C1-INH is bound to the cell surface is unknown.
 
Escherichia coli
 
 O157:H7 is an enteric human pathogen
responsible for diarrhea, hemorrhagic colitis, and the po-
tentially lethal hemolytic uremic syndrome. Multiple viru-
lence determinants have been recognized in 
 
E. coli
 
 O157:
H7, including the Shiga toxin, an ADP-ribosylating en-
zyme that inhibits protein synthesis, and the locus of en-
terocyte effacement, responsible for conferring the attach-
ing and effacing phenotype on intestinal epithelial cells (for
review see references 22 and 23). Our laboratory has iden-
tified an additional potential virulence factor, StcE, a met-
alloprotease that cleaves C1-INH from its apparent full-
length M
 
r 
 
of 105 kD to produce unique 
 
 
 
60–65-kD
species (24). StcE is encoded on pO157, a large plasmid
carried by strains of 
 
E. coli
 
 O157:H7, and is ubiquitous
among isolates of the enterohemorrhagic 
 
E. coli
 
 1 complex
(25). StcE is secreted by a functional type II secretion appa-
ratus also encoded on pO157, and its expression has been
detected in vivo (24, 26).
In this report, we investigate the functional consequence
of the interaction between StcE and C1-INH. We show
that instead of inactivating C1-INH, StcE potentiates the
ability of C1-INH to inhibit classical complement activity
by recruiting the inhibitor to cell surfaces. Additionally,
physical analysis indicates that StcE cleaves C1-INH not in
the RCL, but within its heavily glycosylated NH
 
2
 
-terminal
domain. Finally, we show that StcE-treated C1-INH pro-
vides increased serum resistance to 
 
E. coli
 
, suggesting that
StcE may aid the protection of 
 
E. coli
 
 O157:H7 from com-
plement activity during infection.
 
Materials and Methods
 
Bacterial Strains, Buffers, and Materials.
 
All chemicals were
purchased from Sigma-Aldrich unless stated otherwise. Buffers
used were PBS (10 mM sodium phosphate, 140 mM NaCl, pH
7.4), TBS (20 mM Tris, 150 mM NaCl, pH 7.5), VBS (5 mM
veronal, 145 mM NaCl, pH 7.4), VBS
 
2
 
  
 
(VBS containing 0.15
mM CaCl
 
2 
 
and 0.5 mM MgCl
 
2
 
), and VBS containing 10 mM
EDTA. Recombinant DNA manipulations were performed by
standard methods. pTB4 was constructed by amplifying bases
207–2795 of the 
 
stcE
 
 gene from pO157 by PCR with the primers
 
stcE
 
Sac5
 
 
 
207 (5
 
 
 
-CCGAGCTCCGGCTGATAATAATTCAG-
CCATTTATTTC-3
 
 
 
) and 
 
stcE
 
3
 
 
 
Xba2795 (5
 
 
 
-CCTCGAGTT-
TATATACAACCCTGATTG-3
 
 
 
), and cloning the product
into the SacI-XhoI sites of pET24d(
 
 
 
) (Novagen). WAM2751 is
 
E. coli
 
 strain BL21(DE3) (Novagen) transformed with pTB4.
pTB5 was constructed in the same manner as pTB4 by amplify-
ing the equivalent bases of the 
 
stcE
 
 E435D mutant from pTEG1
(24). WAM2804 is 
 
E. coli
 
 strain BL21(DE3) transformed with
pTB5. StcE
 
 
 
-His, lacking the StcE NH
 
2
 
-terminal signal sequence
and containing a 6xHis tag at the COOH terminus, and StcE
 
 
 
E435D-His, a similar protein with a single amino acid change at
residue 435 (glutamic to aspartic acid) that disrupts the catalytic
activity of the protease, were purified from WAM2751 and
WAM2804, respectively, as previously described (24) and dia-
lyzed into VBS, pH 6.5. Purified C1-INH was obtained from
Advanced Research Technologies and purified kallikrein and C1s
were from Calbiochem. All proteins were stored at 
 
 
 
80
 
 
 
C.
mAbs 3C7 and 4C3 were provided by P.A. Patston (University
of Illinois at Chicago, Chicago, IL).
 
Hemolytic Assays.
 
Sheep erythrocytes were prepared accord-
ing to Mayer (27). Erythrocytes were opsonized with an anti–
sheep red blood cell Ab for 10 min before use. Human serum
(0.5%) was mixed with opsonized erythrocytes (10
 
7 
 
in 50 
 
 
 
l) in
VBS
 
2
 
  
 
to a total volume of 200 
 
 
 
l for 1 h at 37
 
 
 
C before the addi-
tion of 1 ml VBS plus 10 mM EDTA to stop complement activ-
ity. To measure the amount of hemoglobin released by lysed cells,
erythrocytes were pelleted and the OD
 
412 
 
of the supernatant was
measured in a spectrophotometer. The percent lysis was deter-
mined by subtracting the OD
 
412 
 
in the absence of serum and di-
viding by the maximum possible OD
 
412 
 
obtained by lysis of eryth-
rocytes in water. Where indicated, increasing concentrations of
StcE
 
 
 
-His or BSA were incubated with serum overnight at room
temperature before the start of the assay. To determine the effect
of StcE-treated C1-INH on erythrocyte lysis, increasing concen-
trations of StcE
 
 
 
-His or BSA were mixed with 16 
 
 
 
g C1-INH, or
increasing concentrations of C1-INH were mixed with 1 
 
 
 
g
StcE
 
 
 
-His or 1 
 
 
 
g StcE
 
 
 
 E435D-His in a total volume of 149 
 
 
 
l
VBS
 
2
 
  
 
overnight at room temperature before the start of the assay.
Statistical analyses were performed by the unpaired 
 
t
 
 test.
 
Flow Cytometry.
 
8 
 
 
 
g C1-INH was untreated or treated with
1 
 
 
 
g StcE
 
 
 
-His in a total volume of 149 
 
 
 
l VBS
 
2
 
  
 
as described
above before the addition of opsonized sheep erythrocytes and
human serum deficient in complement component C5 (Quidel
Corp.). Erythrocytes were incubated for 10 min at 37
 
 
 
C be-
fore the addition of VBS plus 10 mM EDTA. Cells were washed
with VBS
 
2
 
  
 
and incubated on ice for 30 min with polyclonal
goat anti–human IgG against C1-INH (Cedarlane Laboratories).
Erythrocytes were washed, incubated on ice for 30 min with
FITC-conjugated rabbit anti–goat IgG, and resuspended in
VBS
 
2
 
  
 
for analysis by flow cytometry using a fluorescence-acti-
vated cell sorter (FACSCalibur™; Becton Dickinson). Where in-
dicated, StcE
 
 
 
-His was removed from the assay mixture by ad-
sorption to Ni-NTA agarose beads (QIAGEN) in the presence of
50 mM imidazole before the addition of sheep erythrocytes. To
measure StcE-treated C1-INH saturation kinetics of erythro-
cytes, increasing concentrations of C1-INH were mixed with 1
 
 
 
g StcE
 
  
 
E435D-His before the addition of 10
 
7 
 
sheep erythro-
cytes as described above in the absence of human serum and ana-
lyzed by flow cytometry.
To determine if StcE binds sheep erythrocytes, StcE
 
 
 
-His was
labeled via its primary amines with the Alexa Fluor 488 dye as
described by the manufacturer (Molecular Probes). 5 
 
  
 
10
 
6 
 
sheep
erythrocytes were opsonized as described above, pelleted, and re-
suspended in 500 
 
 
 
l VBS
 
2
 
  
 
before the addition of 250 ng StcE
 
 
 
-
His or Alexa-labeled StcE
 
 
 
-His for 10 min at 37
 
 
 
C. Erythrocytes 
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were pelleted and washed with VBS
 
2
 
  
 
before analysis by flow cy-
tometry. To measure the point at which erythrocytes become
saturated with StcE, increasing concentrations of Alexa-labeled
StcE
 
 
 
-His were added to 10
 
7 
 
sheep erythrocytes for 10 min at
37
 
 
 
C before analysis by flow cytometry as described above.
 
Immunoblot Analyses.
 
1.5 
 
 
 
g purified, activated C1s were un-
treated, treated with 100 ng C1-INH, or treated with C1-INH
in the presence of 50 ng StcE
 
 
 
-His or StcE
 
  
 
E435D-His for 1 h at
37
 
 
 
C in a total volume of 30 
 
 
 
l VBS
 
2
 
 
 
. An equal volume of non-
reducing sample buffer was then added, the samples were heated
to 95–100
 
 
 
C for 5 min, and the proteins were separated on an 8%
SDS-PAGE gel. Proteins were transferred to nitrocellulose and
analyzed by immunoblot as previously described (24) using a
polyclonal goat anti–C1s Ab (Calbiochem).
In other experiments, mAb 4C3 was coupled to protein
A–Sepharose beads as previously described (28) and used to re-
move trace amounts of RCL-cleaved C1-INH from the purified
C1-INH preparation. 1 
 
 
 
g virgin C1-INH was then incubated
with or without 1 
 
 
 
g StcE
 
 
 
-His or 2 
 
 
 
g kallikrein for 18 h at room
temperature before electrophoresis on an 8% reducing SDS-PAGE
gel. Separated proteins were transferred to nitrocellulose and ana-
lyzed by immunoblot as described using a polyclonal anti–human
C1-INH Ab (Serotec), mAb 3C7, or mAb 4C3.
 
Cell Culture.
 
COS-7 cells (provided by D. Paulnock, Uni-
versity of Wisconsin, Madison, WI) were cultured in DMEM
(Invitrogen) with 10% heat-inactivated FCS (Mediatech), nones-
sential amino acids, and penicillin/streptomycin/amphotericin B
(Invitrogen). Cells were transfected with either hC1-INH/
pcDNA3.1(
 
 
 
) or C-serp(98)/pcDNA3.1(
 
 
 
) (provided by A.E.
Davis, Harvard University, Cambridge, MA) using cationic lipids
(Lipofectamine PLUS; Invitrogen). After transfection, cells were
cultured in the presence of G418 (Invitrogen). Recombinant
proteins were metabolically labeled with [
 
35
 
S]methionine (Amer-
sham Biosciences) for 24 h before immunoprecipitation.
 
Immunoprecipitation.
 
100 
 
 
 
l culture supernatants from C1-
INH–transfected COS-7 cells were treated with 10 
 
 
 
g StcE
 
 
 
-His
overnight at room temperature before incubation with polyclonal
goat anti–human C1-INH IgG (Cedarlane Laboratories) and pro-
tein A–Sepharose for 2 h at room temperature. Pellets were
washed three times with TBS, resuspended in sample buffer, and
electrophoresed on 10% reducing SDS-PAGE gels. Gels were
fixed, dried, and visualized with a phosphorimager (Typhoon
8600; Amersham Biosciences). In other experiments, 5 
 
 
 
g C1-
INH was untreated or treated with 5 
 
 
 
g StcE
 
 
 
-His or StcE
 
 
 
E435D-His for 10 min at 37
 
 
 
C in 500 
 
 
 
l buffer (100 mM Tris,
pH 8.0) before the addition of polyclonal goat anti–human C1-
INH IgG. The mixture was rotated for 30 min at 4
 
 
 
C, after
which 20 
 
 
 
l of a protein A–Sepharose slurry was added for 2 h.
The protein A–Sepharose beads were subsequently washed three
times in buffer before immunoblot analysis with an anti-StcE Ab.
 
Kallikrein Activity Assay.
 
Increasing concentrations of C1-
INH were mixed with 250 ng StcE
 
 
 
-His in a total volume of 100
 
 
 
l assay buffer (50 mM Tris, pH 8.0, 100 mM NaCl) at room
temperature overnight, after which EDTA was added to 5 mM
to stop the reaction. Purified kallikrein was diluted to 100 ng in
50 
 
 
 
l assay buffer and mixed with C1-INH for 1 h at 37
 
 C be-
fore adding the chromogenic substrate S-2302 (Chromogenix) to
each tube. Tubes were incubated at room temperature for 30 min
before determining the absorbance of the substrate at 410 nm in a
spectrophotometer. Percent kallikrein activity was determined by
subtracting the OD410 in the absence of kallikrein and dividing by
the maximum possible OD410 obtained by kallikrein activity in
the absence of C1-INH.
Serum Resistance. 8  g C1-INH was untreated or treated with
1  g StcE -His in a total volume of 176  l VBS2  overnight at
room temperature, after which human serum was added to 2%. E.
coli K-12 strain C600 was grown to an OD595 of 0.5 in Luria-Ber-
tani (LB) broth at 37 C with aeration before being washed once
and resuspended with an equivalent volume of VBS2 . 20  l bac-
teria were added to the reactions, incubated at 37 C for 1 h, and
10  l aliquots were mixed with VBS plus 10 mM EDTA to stop
complement activity. 10-fold serial dilutions of bacteria were
plated on LB agar and percent survival was determined by divid-
ing CFUs by the total number of bacteria after 1 h in the absence
of serum. Statistical analysis was performed by the unpaired t test.
Results
Inhibition of Classical Complement-mediated Erythrocyte Lysis
by StcE. Previous research from our laboratory demon-
strated that StcE, a metalloprotease secreted by E. coli
O157:H7, cleaves the serum protein C1-INH from its ap-
parent Mr of 105 kD to produce  60–65-kD species (24).
As C1-INH is an essential regulator of the classical comple-
ment pathway, we examined the effect of StcE on the
classical complement-mediated lysis of sheep erythrocytes.
Human serum was mixed overnight with increasing con-
centrations of StcE or the control protein BSA before add-
ing to opsonized sheep erythrocytes for 1 h at 37 C. The
reaction was stopped with EDTA and the amount of he-
moglobin released by lysed erythrocytes into the superna-
tant was measured. Serum alone lysed 75.0% ( 2.7% SEM)
of erythrocytes and BSA had no effect on the ability of
serum to lyse erythrocytes (Fig. 1). At higher concentra-
tions, though, StcE significantly reduced classical comple-
ment-mediated erythrocyte lysis compared with equivalent
amounts of BSA (2  g, P   0.01; 4  g, P   0.005).
StcE Potentiates C1-INH–mediated Inhibition of Classical
Complement. Although StcE cleaves the serum compo-
nent C1-INH, the data represented in Fig. 1 do not impli-
cate the serpin directly in StcE-mediated classical comple-
Figure 1. StcE reduces the classical complement-mediated erythrocyte
lysis by human serum. 1  l human serum was untreated or treated with
increasing concentrations of StcE -His or BSA overnight before the addition
of 107 opsonized sheep erythrocytes for 1 h at 37 C, in triplicate. Unlysed
cells were pelleted and the OD412 of the supernatant was measured in a
spectrophotometer (*, P   0.0077; **, P   0.0028; unpaired t test).
Suspension in distilled water was used to determine the absorbance of
100% lysis of erythrocytes.Potentiation of C1 Esterase Inhibitor by E. coli O157:H7 1080
ment inhibition. To examine if StcE-treated C1-INH plays
a role in this process, we mixed purified C1-INH with in-
creasing concentrations of StcE or BSA overnight and
added this mixture to human serum and opsonized sheep
erythrocytes for 1 h at 37 C. As before, the reaction was
stopped with EDTA and the amount of hemoglobin re-
leased by lysed erythrocytes into the supernatant was mea-
sured. The addition of 0.4 IU untreated C1-INH to the as-
say decreased erythrocyte lysis from 82.9 ( 1.1% SEM) to
33.7% ( 1.8% SEM; Fig. 2 A), demonstrating the effective
role of C1-INH in the inhibition of classical complement
activity. Although BSA-treated C1-INH was unchanged in
inhibitory activity, 0.4 IU StcE-treated C1-INH reduced
erythrocyte lysis to between 1.5 ( 0.5% SEM) and 0.1%
( 0.1% SEM) of total.
To confirm the effect of StcE on C1-INH–mediated in-
hibition of erythrocyte lysis, increasing concentrations of
C1-INH were untreated or treated with StcE -His over-
night before the addition of human serum and opsonized
sheep erythrocytes. Increasing concentrations of untreated
C1-INH (0.05–0.4 IU) resulted in a dose-dependent de-
crease in erythrocyte lysis, ranging from 76.5 ( 2.4% SEM)
to 27.5% ( 1.1% SEM; Fig. 2 B). However, in the pres-
ence of 1  g StcE -His, the same concentrations of C1-
INH significantly reduced lysis below that of untreated C1-
INH (ranging from 46.7 [ 1.5% SEM] to 2.8% lysis
[ 1.3% SEM], all p-values  0.0005). These results demon-
strate the direct role of StcE-treated C1-INH in the de-
crease of classical complement-mediated erythrocyte lysis.
Additional experiments confirm that StcE-treated C1-INH
continues to react with its natural targets C1r and/or C1s to
mediate the inhibition of classical complement, maintaining
the target specificity of the serpin (unpublished data).
StcE Binds Erythrocyte Surfaces. To understand how
StcE might potentiate C1-INH, we asked if StcE could in-
teract with erythrocytes, thereby acting as a binding protein
for C1-INH on cell surfaces. 250 ng unlabeled StcE -His
or a form of StcE -His fluorescently labeled via its primary
amines with the Alexa Fluor 488 dye (Alexa-StcE -His)
were added to opsonized sheep erythrocytes for 10 min at
Figure 2. StcE potentiates C1-INH–mediated inhibition of classical
complement. (A) 16  g C1-INH was untreated or treated with increasing
concentrations of StcE -His or BSA overnight at room temperature before
the addition of 1  l human serum and 107 opsonized sheep erythrocytes,
in triplicate. Erythrocytes were incubated at 37 C for 1 h, pelleted, and
the OD412 of the supernatant was measured in a spectrophotometer. The
point indicated by   lacked C1-INH. (B) Increasing amounts of C1-INH
were untreated or treated with 1  g StcE -His overnight at room temper-
ature before the addition of human serum and opsonized sheep erythrocytes
as described in A, in triplicate. Suspension in distilled water was used to
determine the absorbance of 100% lysis of erythrocytes (all p-values
 0.0005; unpaired t test).
Figure 3. StcE binds erythrocyte surfaces. (A) 250 ng StcE -His or
Alexa-StcE -His was incubated with opsonized sheep erythrocytes for 10
min at 37 C, after which the cells were washed and the binding of StcE
was detected in a flow cytometer. (B) Increasing concentrations of Alexa-
StcE -His (0.1–25.6  g) were added to sheep erythrocytes. StcE binding
was detected by flow cytometry as described above, and the geometric
mean fluorescence for each sample was plotted against the corresponding
concentration of Alexa-StcE His.Lathem et al. 1081
37 C. Erythrocytes were pelleted and washed with VBS2 
before analysis by flow cytometry. Erythrocytes treated
with Alexa-labeled StcE -His showed 80-fold greater mean
fluorescence compared with cells treated with unlabeled
StcE -His (Fig. 3 A), demonstrating a direct interaction be-
tween these cells and the protease. Furthermore, we ob-
served that StcE continues to bind sheep erythrocytes even
at lower temperatures (0–4 C), suggesting that this interac-
tion is not mediated by an active cellular process (not de-
picted). To determine if the interaction between erythro-
cytes and StcE is specific and therefore saturable, we mixed
increasing concentrations of Alexa-labeled StcE -His with
107 sheep erythrocytes as described above. We observed
that this number of erythrocytes becomes saturated with
StcE -His at 3.2  g of the protease in 500  l (Fig. 3 B).
Based on the calculated molecular weight of StcE -His, at
this concentration we estimate  1.8   106 molecules of
StcE are bound per erythrocyte.
StcE Localizes C1-INH to Erythrocyte Surfaces. Based on
the ability of StcE to directly bind erythrocytes, we asked
if StcE could localize C1-INH to erythrocyte surfaces,
thereby possibly increasing the local concentration of inhib-
itor at the site of potential lytic complex formation. C1-
INH was untreated or treated with StcE -His overnight be-
fore the addition of opsonized sheep erythrocytes and
C5-deficient human serum (to prevent formation of the
membrane attack complex and lysis of the cells) for 10 min
at 37 C. Erythrocytes were washed, treated with an Ab
against C1-INH, and washed again before the addition of
an FITC-conjugated secondary Ab. Deposition of C1-INH
was subsequently analyzed by flow cytometry. Little to no
C1-INH binding was measured on erythrocytes treated
with only StcE -His or native C1-INH compared with
mock-treated cells (Fig. 4 A). However, increased deposi-
tion of C1-INH was detected on erythrocytes mixed with
0.2 IU StcE-treated C1-INH. Similar results were observed
in the absence of human serum, indicating that serum com-
ponents or complement activation are not required for the
localization of StcE-treated C1-INH to erythrocyte sur-
faces. As we observed with the interaction between StcE
and sheep erythrocytes, StcE-treated C1-INH continues to
bind the cells at 0–4 C (not depicted).
The results suggest that StcE may directly mediate the
binding of C1-INH to the cell surface. To test this possibil-
ity, C1-INH was incubated with or without StcE -His
overnight as described earlier, after which Ni-NTA agarose
beads were added to the samples in the presence of 50 mM
imidazole to specifically remove the 6xHis-tagged StcE pro-
tein from the assay. The agarose beads were pelleted and the
supernatants were mixed with sheep erythrocytes and ana-
lyzed by flow cytometry as described above. In the absence
of the protease, StcE-treated C1-INH no longer binds to
erythrocyte surfaces (Fig. 4 B), indicating that StcE itself is
required to sequester C1-INH to erythrocytes. The absence
Figure 4. C1-INH binds erythrocyte
surfaces in the presence of StcE. (A) 8  g
C1-INH was untreated or treated with
1  g StcE -His overnight at room tem-
perature. C5-deficient human serum
was added to opsonized sheep erythro-
cytes in the presence of 8  g C1-INH,
1   g StcE -His, C1-INH, and StcE -
His, or buffer alone (mock) for 10 min
at 37 C. Erythrocytes were washed and
polyclonal goat anti–human C1-INH
IgG was added to cells. C1-INH binding
was detected with FITC-conjugated anti–
goat IgG in a flow cytometer. (B) 8  g
C1-INH was incubated with or without
1  g StcE -His overnight at room tem-
perature before the addition of 50 mM
imidazole and Ni-NTA agarose beads to
remove StcE -His from the sample.
Opsonized sheep erythrocytes were
added for 10 min at 37 C and C1-INH
binding was detected as described. As a
control for StcE-treated C1-INH binding,
StcE -His was not removed from one
sample before analysis. (C) Increasing
concentrations of C1-INH (0.25–16  g)
were mixed with 1  g StcE  E435D-His
overnight at room temperature before the
addition of opsonized erythrocytes. C1-
INH binding was detected in a flow
cytometer as described above, and the
geometric mean fluorescence for each
sample was plotted against the corre-
sponding concentration of C1-INH. (D) 5  g C1-INH was untreated or treated with 5  g StcE -His or StcE  E435D-His for 10 min before being
immunoprecipitated with an anti–C1-INH Ab. Precipitated proteins were separated by reducing SDS-PAGE, transferred to nitrocellulose, and probed
with an anti-StcE Ab as described in Materials and Methods.Potentiation of C1 Esterase Inhibitor by E. coli O157:H7 1082
of StcE -His from the Ni-NTA agarose-treated samples and
the presence of equivalent amounts of C1-INH between
Ni-NTA agarose-treated and untreated samples were con-
firmed by immunoblot analyses (unpublished data).
To determine the level at which erythrocytes become
saturated with StcE-treated C1-INH, we mixed StcE 
E435D-His (a mutant form of the protein containing a sin-
gle amino acid change from glutamic to aspartic acid at po-
sition 435 that is unable to cleave C1-INH; reference 24)
with increasing concentrations of C1-INH (from 0.25 to
16  g) before the addition of opsonized sheep erythrocytes
as described above. We chose to use StcE  E435D-His in
this experiment so as to measure the saturation of sheep
erythrocytes with C1-INH without the creation of StcE-
cleaved C1-INH, which might reduce the levels of the
serpin bound to the cell surface, thereby increasing the
amount needed to saturate the cells. We observed that in
the presence of 1  g StcE  E435D-His, this number of
erythrocytes becomes saturated with C1-INH at 4  g, or
0.1 IU, of the serpin (Fig. 4 C). Based on the observed mo-
lecular weight of mature C1-INH and assuming uniform
binding of the primary and secondary antibodies to their
antigens, at this concentration we estimate  2.25   106
molecules of C1-INH are bound per erythrocyte. Finally,
to determine if C1-INH and StcE can interact in solution
(before binding erythrocytes), C1-INH was mixed with ei-
ther StcE -His or StcE  E435D-His for 10 min at 37 C be-
fore immunoprecipitating the mixture with an anti–C1-
INH Ab. After separating the immunoprecipitated proteins
by SDS-PAGE and transferring them to nitrocellulose,
both StcE -His and StcE  E435D-His were detected with
an anti–StcE -His Ab, demonstrating that a complex of
StcE and C1-INH can be formed in solution (Fig. 4 D).
Cleavage of C1-INH by StcE Is Not Necessary to Protect
Cells against Complement Activity. To test if the proteolysis
of C1-INH by StcE is necessary to provide erythrocytes in-
creased protection against classical complement activity over
that of untreated C1-INH, we mixed C1-INH with either
StcE -His or the proteolytically inactive StcE  E435D-His.
After overnight incubation, the samples were added to hu-
man serum and opsonized sheep erythrocytes for 1 h at
37 C before determining the amount of hemoglobin re-
leased into the supernatant by the lysed cells as described
above. In the presence of 0.2 IU C1-INH, human serum
lysed 75.8% ( 1.5% SEM) of the erythrocytes, whereas
StcE -His–treated C1-INH significantly decreased erythro-
cyte lysis to 25.4% ( 3.5% SEM, P   0.005; Fig. 5 A). In-
terestingly, the cleavage of C1-INH by StcE is not required
for the protection of erythrocytes from complement activ-
ity, as StcE  E435D-His–treated C1-INH was able to signif-
icantly reduce the lysis of the cells to 16.7% ( 1.3% SEM,
P   0.005). The difference in the amount of erythrocyte ly-
sis between the StcE -His– and StcE  E435D-His–treated
C1-INH samples was not significant (P   0.05).
To determine if the subsequent cleavage of C1-INH by
StcE affects the binding of the serpin to erythrocytes, we
incubated 2  g C1-INH with 1  g StcE -His or StcE 
E435D-His overnight before assessing the levels of surface-
associated C1-INH by flow cytometry as described above.
Indeed, the levels of C1-INH in the presence of StcE 
E435D-His on erythrocyte surfaces are 22-fold higher than
in the presence of StcE -His (Fig. 5 B), suggesting that
once cleaved by StcE, C1-INH no longer binds to erythro-
cytes. In total, the data presented in Figs. 4 and 5 demon-
strate that the increased protection of erythrocytes by StcE-
treated C1-INH is dependent upon the physical presence
of StcE and not the cleavage of C1-INH by the protease.
StcE Is Unable to Potentiate C1-INH in the Absence of
Cells. Data presented so far demonstrate the ability of StcE
to localize C1-INH to erythrocytes, thereby providing in-
creased complement-inhibiting activity at the cell surface.
To determine if this potentiation can occur in solution (i.e.,
in the absence of cells), we measured whether StcE affects
the ability of C1-INH to inhibit kallikrein, another C1-
INH–regulated molecule, by monitoring the cleavage of a
chromogenic substrate of kallikrein, S-2302 (H-d-Prolyl-
l-phenylalanyl-l-arginine-p-nitroaniline dihydrochloride).
Figure 5. Cleavage of C1-INH by StcE is not necessary to bind erythro-
cytes or provide protection against classical complement. (A) Classical
complement-mediated erythrocyte lysis was determined as described in
Materials and Methods in the presence of 8  g C1-INH, C1-INH and 1  g
StcE -His, or C1-INH and an enzymatic point mutant of StcE, 1  g
StcE  E435D-His (*, P   0.005; unpaired t test). (B) 2  g C1-INH was
untreated or treated with 1  g StcE -His or StcE  E435D-His before the
addition of sheep erythrocytes as described in Materials and Methods.
Erythrocytes were washed and polyclonal goat anti–human C1-INH IgG
was added to cells. C1-INH binding was detected with FITC-conjugated
anti–goat IgG in a flow cytometer.Lathem et al. 1083
Increasing concentrations of C1-INH were untreated or
treated with StcE -His overnight at room temperature, after
which the samples were allowed to react with kallikrein for
1 h at 37 C. The C1-INH/kallikrein mixtures were subse-
quently incubated with S-2302 for 30 min at room temper-
ature before determining total kallikrein activity by mea-
suring the change in absorbance of the samples in a
spectrophotometer. For the purpose of this assay, kallikrein
in the absence of C1-INH was considered to be 100% ac-
tive. As expected, increasing concentrations of C1-INH re-
sulted in a dose-dependent decrease in kallikrein activity,
ranging from 88.8 ( 2.6% SEM) to 10.3% ( 1.3% SEM)
activity (Fig. 6 A). The addition of StcE-treated C1-INH to
the assay did not significantly alter the inactivation of kal-
likrein compared with untreated C1-INH.
We also examined the ability of StcE-treated C1-INH to
interact with an excess of C1s in solution, thereby forming
an SDS-insoluble complex. 1.5  g purified, activated C1s
was mixed with 100 ng C1-INH and 50 ng StcE -His or
StcE  E435D-His for 1 h at 37 C before separating the
proteins by nonreducing SDS-PAGE and analyzing the
mixture by immunoblot with an anti-C1s Ab. The high
molecular weight band in samples containing C1-INH that
are absent from the sample containing C1s alone are indic-
ative of the C1s–C1-INH interaction. If StcE were able to
potentiate C1-INH in solution, an increase in the intensity
of the C1s–C1-INH band would be visible. However, this
does not appear to be the case (Fig. 6 B). Thus, the mecha-
nism of StcE-mediated potentiation of C1-INH is depen-
dent on the presence of cell surfaces upon which the pro-
tease–serpin complex can bind.
Interaction of StcE with the NH2 Terminus of C1-INH.
The ability of StcE to interact with C1-INH while main-
taining the inhibitory activity of the molecule suggests that
Figure 6. StcE is unable to potentiate C1-INH in the absence of cells.
(A) Increasing concentrations of C1-INH (0–1.0  g) were mixed with
250 ng StcE -His overnight at room temperature and incubated with 100
ng kallikrein for 1 h at 37 C before the addition of S-2302, in triplicate.
Absorbance of the chromogenic substrate was measured at 410 nm in a
spectrophotometer after 30 min at room temperature. 100% kallikrein
activity was determined in the absence of C1-INH. (B) An excess of
purified, activated C1s (1.5  g) was untreated or treated with 100 ng C1-
INH in the absence or presence of 50 ng StcE -His or StcE  E435D-His
for 1 h at 37 C before being separated by nonreducing SDS-PAGE and
analyzed by immunoblot with an anti-C1s Ab. The gray arrow indicates
the presence of uncomplexed C1s and the black arrow indicates the
presence of C1s bound to C1-INH in an SDS-insoluble complex.
Figure 7. StcE interacts with the aminoterminal domain of C1-INH.
(A) StcE-treated C1-INH is nonreactive with mAbs against the NH2
terminus of and RCL-inserted C1-INH. 1  g virgin C1-INH was untreated
or treated with 1  g StcE -His or 2  g kallikrein overnight at room tem-
perature, separated by electrophoresis on 8% reducing SDS-PAGE gels,
transferred to nitrocellulose, and analyzed with a polyclonal anti–human
C1-INH Ab (left), mAb 3C7 (middle), or mAb 4C3 (right). (B) StcE
does not cleave C-serp(98), a recombinant C1-INH molecule truncated
at amino acid 98. COS-7 cells were transfected with hC1-INH/
pcDNA3.1( ) or C-serp(98)/pcDNA3.1( ) and metabolically labeled
with [35S]methionine. 100  l supernatants were untreated or treated with
10  g StcE -His overnight, immunoprecipitated with polyclonal anti–
human C1-INH IgG protein A–Sepharose, and separated by electro-
phoresis on a 10% reducing SDS-PAGE gel.Potentiation of C1 Esterase Inhibitor by E. coli O157:H7 1084
StcE may bind C1-INH in the heavily glycosylated NH2-
terminal domain, leaving the serpin domain unaffected.
Therefore, to further characterize the site(s) of cleavage by
StcE, we examined StcE-treated C1-INH with the mAbs
3C7 and 4C3, directed against the amino terminus of C1-
INH (Patston, P.A., personal communication) and the
RCL-inserted form of C1-INH (29), respectively. As most
preparations of purified C1-INH contain trace amounts of
RCL-cleaved C1-INH, we removed this species of C1-
INH from the mixture by immunoprecipitation with mAb
4C3 before analysis. Virgin C1-INH was treated with StcE
or kallikrein, a serine protease inactivated by C1-INH via
its interaction with and cleavage of the RCL, before analy-
sis by immunoblot with a polyclonal anti–human C1-INH
Ab (Fig. 7 A, left), 3C7 (Fig. 7 A, middle), or 4C3 (Fig. 7
A, right). As expected, analysis with 3C7 detected both vir-
gin C1-INH and kallikrein-reacted C1-INH, but did not
detect StcE-cleaved C1-INH, indicating a modification of
the C1-INH NH2 terminus by StcE. Additionally, analysis
with 4C3 detected RCL-inserted C1-INH produced upon
interaction with kallikrein, but not virgin C1-INH or
StcE-treated C1-INH.
To confirm that StcE interacts with the NH2-terminal
domain of C1-INH, we examined the ability of StcE to
cleave a recombinant C1-INH protein lacking this region.
Coutinho et al. (16) demonstrated that C-serp(98), a re-
combinant C1-INH molecule lacking the NH2-terminal
amino acids 1–97 and containing only the serpin domain,
binds its serine protease substrates identically to wild-type
C1-INH and is effective in inhibiting C1 activity in
hemolytic assays. We expressed recombinant, full-length
human C1-INH (hC1-INH) and C-serp(98) in COS-7
cells and harvested the culture media after 24 h in the
presence of [35S]methionine. Samples were untreated or
treated with StcE -His overnight before immunoprecipi-
tating metabolically labeled protein with polyclonal anti–
human C1-INH IgG. Both hC1-INH and C-serp(98) mi-
grated at the appropriate molecular weights on a reducing
SDS-PAGE gel, however, only hC1-INH was cleaved by
StcE -His. C-serp(98) was unaffected by the protease (Fig.
7 B). These analyses further support the evidence that StcE
does not inactivate C1-INH, but instead interacts with the
heavily glycosylated NH2-terminal domain of C1-INH,
leaving the serpin domain available for interaction with
C1-INH targets.
Increased Bacterial Serum Resistance in the Presence of StcE-
treated C1-INH. StcE is secreted by E. coli O157:H7 (24),
a human pathogen that may come in contact with blood or
blood products during the course of an infection. Based on
its ability to enhance C1-INH–mediated inhibition of clas-
sical complement, we examined if StcE could provide se-
rum resistance to E. coli. As E. coli O157:H7 is naturally se-
rum resistant and contains a variety of factors that could
contribute to its protection from complement (30), we
chose to assess the role of StcE-treated C1-INH in the sur-
vival of a serum-sensitive strain of E. coli. E. coli K-12 strain
C600 was grown to mid-log phase, pelleted, and resus-
pended in an equivalent amount of VBS2  before the addi-
tion of human serum and 0.2 IU C1-INH or StcE-treated
C1-INH. Bacteria were incubated at 37 C for 1 h, serially
diluted, and plated onto LB agar to determine the numbers
of surviving CFUs. In the presence of human serum alone,
0.07% ( 0.06% SEM) of bacteria survived, demonstrating
the exquisite serum sensitivity of E. coli strain C600 (Fig.
8). The addition of StcE -His to bacteria at the beginning
of the assay had no significant effect on survival (0.04% sur-
vival,   0.03% SEM). As expected, the addition of un-
treated C1-INH increased survival of bacteria to 3.9%
( 0.9% SEM). The addition of StcE-treated C1-INH to
the assay, however, caused a significant increase in bacterial
survival over untreated C1-INH (16.5% survival,  1.9%
SEM; P   0.005), indicating a contribution to comple-
ment resistance by StcE.
Discussion
In this report, we define the outcome of the interaction
between StcE, a metalloprotease secreted by the enteric
pathogen E. coli O157:H7, and its apparent target, the ser-
pin C1-INH. Rather than reducing or destroying its serpin
activity, this interaction in effect enhances the ability of
C1-INH to down-regulate the classical complement cas-
cade, thereby protecting cells from the lytic effects of com-
plement activity. Specifically, we found that the addition of
StcE-treated C1-INH to opsonized sheep erythrocytes and
human serum significantly decreased erythrocyte lysis be-
low that of equivalent amounts of native C1-INH (Fig. 2).
The decrease is specific for StcE and C1-INH, as BSA had
no effect on erythrocyte lysis. We also observed a signifi-
cant decrease in complement activity when human serum
was treated with StcE before the addition of sheep erythro-
cytes (Fig. 1). This is likely due to the activity of StcE on
Figure 8. StcE provides increased serum resistance to E. coli K-12 by
the potentiation of C1-INH. 8  g C1-INH was untreated or treated
with 1  g StcE -His overnight. E. coli strain C600 was grown in LB
broth at 37 C to midlogarithmic phase and diluted at 1:10 into a buffer
containing 2% human serum and either 8  g C1-INH, 1  g StcE -His,
C1-INH, and StcE -His, or no additional protein, in triplicate. Bacteria
were incubated at 37 C for 1 h, serially diluted, and plated onto LB agar.
Percent survival was determined by comparing the number of CFUs to
bacteria incubated under the same conditions without serum (*, P   0.0037;
unpaired t test).Lathem et al. 1085
the endogenous C1-INH found in serum, although other
potential targets cannot be ruled out. Furthermore, analysis
of complement component deposition on erythrocyte sur-
faces indicates that StcE-treated C1-INH continues to act
on its natural targets C1r and/or C1s.
Interestingly, we observed that StcE was unable to poten-
tiate C1-INH activity in the absence of cells (Fig. 6). These
data suggest that rather than modifying C1-INH directly to
increase its inhibitory ability, StcE might be tethering the
serpin to cell surfaces, thereby increasing the local concen-
tration of the inhibitor at the sites of potential lytic complex
formation. Functional C1-INH has been identified on the
surface of multiple cell types including endothelial cells and
platelets (20, 21). Moreover, work by Patston and Schapira
(31) demonstrated that C1-INH binds extracellular matrix
proteins such as collagen IV and laminin while retaining in-
hibitory activity against C1s. C1-INH cross-linked by tis-
sue transglutaminase to the extracellular matrix may influ-
ence the local regulation of C1-INH–controlled proteolytic
pathways (32) and recombinant, GPI-anchored C1-INH–
expressing porcine endothelial cells are protected from hu-
man complement-mediated lysis (33). Indeed, ex vivo rep-
erfusion of pig liver with C1-INH showed immunoreactive
C1-INH localized to the sinusoidal endothelium and re-
duced plasma C3 activation (34).
With this in mind, we investigated whether StcE could
localize C1-INH to erythrocyte surfaces, thereby increas-
ing the local concentration of the inhibitor at sites of
potential lytic complex formation. We found that StcE-
treated C1-INH, but not native C1-INH, binds erythro-
cyte surfaces (Fig. 4 A), providing a plausible explanation
for the reduced classical complement activity observed.
The StcE-mediated binding of C1-INH to cell surfaces
would also explain why StcE had no effect on C1-INH–
mediated inhibition of kallikrein (Fig. 6) because this assay
was performed in the absence of cells. However, as the
contact activation pathway is initiated upon the interaction
of Factor XII and prekallikrein with negatively charged
surfaces (6), it is feasible that StcE-treated C1-INH may
down-regulate this cascade in a manner similar to that ob-
served with classical complement.
How does StcE-treated C1-INH obtain the capacity to
bind to cells? In some cases, a change in the structure of C1-
INH allows the altered molecule to bind to receptor(s)
on the cell surface. For instance, desialylated C1-INH is
thought to interact with hepatic asialoglycoprotein receptors
(35), whereas C1-INH–C1s complexes bind to the low
density lipoprotein receptor–related protein, LRP (36).
Rather than modifying C1-INH in this way, however, our
data indicate that StcE sequesters C1-INH to erythrocytes
by itself binding to cells (Fig. 3) and acting as a “bridge” be-
tween the serpin and the cell surface (Fig. 5). Indeed, the
cleavage of C1-INH by StcE is unnecessary to provide in-
creased protection against complement activity, as a point
mutant of StcE defective in proteolytic activity against C1-
INH protects erythrocytes to similar levels as wild-type StcE
in vitro (Fig. 5 A). The interaction between StcE and eryth-
rocytes is specific, saturating the cells at  1.8   106 mole-
cules of StcE per cell (Fig. 3 B). In turn, this allows a high
affinity interaction between C1-INH and erythrocytes,
reaching 2.25   106 molecules of C1-INH per cell in the
presence of 1  g StcE. This amount of C1-INH (0.1 IU) is
well within the physiological concentration of C1-INH
found in serum, suggesting that this interaction might be bi-
ologically relevant in vivo. Although it appears that the ratio
of C1-INH to StcE is  1:1, this might be due to the het-
erogeneous nature of C1-INH (native, inactivated, and
variably glycosylated forms of the molecule), leaving only a
fraction of the population of C1-INH able to interact with
StcE. Alternatively, StcE may act as a coligand to a multim-
eric molecule capable of binding C1-INH and other com-
ponents. Future analyses of the binding requirements of
StcE and C1-INH will address this possibility.
In our model, the initial interaction between StcE and
the NH2-terminal region of C1-INH at the cell surface al-
lows the serpin to inactivate its targets via the exposed RCL
at the site of C1 complex formation. This occurs before the
eventual cleavage of C1-INH by StcE and the subsequent
release of the serpin from the cell surface, thereby freeing
StcE to interact with another molecule of C1-INH (Fig. 9).
Indeed, we observed increased levels of C1-INH bound to
erythrocytes in the presence of the proteolytically inactive
StcE mutant compared with StcE -His, supporting the no-
tion of C1-INH turnover at the cell surface (Fig. 5 B).
Thus, the relatively slow cleavage rate of C1-INH by StcE
(24) may actually be beneficial to the potentiation of the
serpin, as a more rapid rate of catalysis might not allow
enough time for the inactivation of the C1 complex to oc-
cur. Additionally, the interaction of StcE with the NH2-ter-
minal region of C1-INH (Fig. 7) while bound to the cell
surface likely permits continued access of the serpin domain
to its targets without compromising its activity. The binding
of StcE to host cells might also allow the protease to be car-
ried to sites distal to E. coli O157:H7 colonization in a man-
ner similar to the Shiga toxin (37, 38), thereby affecting C1-
INH-regulated processes outside the local environment of
Figure 9. Model of the mechanism by which StcE potentiates C1-INH-
mediated inhibition of classical complement. (1) StcE interacts with the
cell surface. (2) StcE binds the NH2-terminal domain of C1-INH, sequester-
ing the serpin to the cell surface. Alternatively, StcE may interact with
C1-INH before binding to the cell surface. (3) Cell-bound C1-INH
binds to C1r and/or C1s of the C1 complex via the RCL, inactivating the
serine protease. (4) StcE cleaves within the NH2 terminus of C1-INH,
releasing the serpin/serine protease complex and a smaller, aminoterminal
cleavage fragment of C1-INH from the cell surface. (5) StcE binds another
C1-INH molecule and repeats the cycle as described above. Note that the
figure is not drawn to scale.Potentiation of C1 Esterase Inhibitor by E. coli O157:H7 1086
bacterial infection. Finally, the observation that cell-bound
C1-INH might affect leukocyte adhesion (39) suggests StcE
could influence the migration of inflammatory mediators to
the sites of enterohemorrhagic E. coli colonization.
The complement system is an essential means of host
defense against invading organisms, however, pathogenic
bacteria have developed multiple ways to subvert comple-
ment activity. Capsules and long O-polysaccharide side
chains of LPS can effectively prevent the formation of the
membrane attack complex at bacterial cell surfaces (for re-
view see references 40 and 41), and general metallopro-
teases such as the Serratia marcescens 56-kD protease (42, 43)
and the Pseudomonas aeruginosa elastase (44) can proteolyti-
cally inactivate complement components. Additionally, the
sequestration of complement inhibitors to bacterial surfaces
can reduce complement activity and promote serum resis-
tance. Examples include the binding of Factor H by the
outer membrane protein OspE to Borrelia burgdorferi surfaces
(45) and C4b-binding protein by the well-studied M pro-
tein of group A streptococci (46, 47). In this report we
demonstrate that StcE-treated C1-INH acts in a similar
manner by providing increased serum resistance to E. coli
over native C1-INH (Fig. 8). By preventing complement
activity at such an early stage in the pathway via the re-
cruitment of C1-INH to cells, StcE may also reduce the
opsonization of E. coli O157:H7 by C3b and the produc-
tion of the chemoattractant anaphylatoxins C3a and C5a.
Because StcE is a secreted protein (24), the protection
against complement activation may extend to the colonic
epithelial cells colonized by E. coli O157:H7.
The genome of E. coli O157:H7 contains other potential
serum-resistance loci, including homologues of traT and
the   bor gene encoded on the 933W prophage (30, 48). As
such, StcE likely acts in concert with other factors to pre-
vent complement activation. In addition, the StcE-cleaved
aminoterminal domain of C1-INH may contain unidenti-
fied functions not previously associated with native C1-
INH, much like the smaller, cleaved “a” fragments of vari-
ous complement components. The effect of StcE on the
control of other C1-INH–regulated targets remains to be
investigated, however, based on our data, StcE may well
have profound consequences on multiple aspects of E. coli
O157:H7 pathogenesis.
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